EMBLAVEO: catchy name & innovative antibiotic
Enterobacterales-MBL-AVibactam-aztrEOnam
Aztreonam/avibactam is being developed on the rationale that
⚡️Aztreonam isn't hydrolyzed by MBL enzymes
⚡️Avibactam takes care of
serine β-lactamases, eg ESBL/AmpC , co-produced by MBL
The removal of #HIV- and #LGBTQ-related resources from the websites of the @CDCgov and other health agencies is deeply concerning.
Access to this information is crucial for ID and HIV health care professionals.
Our full statement: https://t.co/xcqdZ6515p
📰 Extra! Extra! Read all about the 2024 updates to the IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Below are highlights from the Notable Updates from 2023 section. For more info: https://t.co/lfiGWbqo6y
#AntimicrobialResistance#IDTwitter
The largest study of Pseudomonas endocarditis to date
🆕️🔥#JAC@Shahnanigans1@ryankshields
Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Combination therapy did not improve clinical outcomes
#IDXposts#IEwiki https://t.co/v6yb9Sn1BV
Is anaerobic coverage necessary for aspiration pneumonia with metronidazole or Augmentin?
NEJM JWatch reports from a large retro study with N ~ 4000
Findings show no added mortality benefit but an increased risk of CDI
https://t.co/5vFxx22wir
#IDTwitter#IDXposts
🔥 Just published 🔥
@IDSAInfo 2024 Guideline Update on the Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation of Complicated Intra-abdominal Infections in Adults, Children, and Pregnant People #idxposts https://t.co/cGbWkyugGk
🆕️⚡️#JAC
Clinical outcomes in patients infected with ertapenem only resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales #IDXposts#CRE https://t.co/7x0iZs77ap
💥BLING III RCT
➡️Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis
⭐The observed difference in 90-day mortality did not meet statistical significance in the primary analysis.
⭐A clinically important benefit with CI is possible.
🔥ORACLE🔥 @yourICM@TrubianoJason
A Pilot RCT of Direct Oral Challenge(DOC) vs Routine Care in Low-Risk Penicillin Allergy in Critical Illnes
This study supports the safety & efficacy of DOC in low-risk[PEN -FAST< 3] penicillin allergy in ICU #IDXposts
https://t.co/8B0nyeeFl3
🔥DOTS🔥
The most anticipated RCT #ESCMIDGLOBAL2024 Dalbavancin is non-inferior to SOC by clinical efficacy for complicated SAB incl Rt sided IE
2 doses Dalba 1500 mg on days 1 & 8 or 4-8 wks of SOC(cefaz or naf:MSSA;vanc or dapto:MRSA)
DOOR at D70
Slides shared by @LordAlirezaF
Everyone who's treating MRSA Bacteremia should read this article now!
An excellent review by @VanceFowler5 et Al @CIDJournal
Persistent MRSA Bacteremia: Resetting the Clock for Optimal Management
🌟Excellent figures 🌟
@snap_trial
Thoughts 🤔 #IDTwitter
https://t.co/9A9drvhWbF
In case you missed it--this one's big!!🔥🔥
in @JAMAInternalMed we found inappropriate diagnosis of #pneumonia to be common and abx treatment harmful. Similar parallels to ASB--> highest risk in older adults with dementia & altered mental status. https://t.co/kFaq6s5Xak
🆕️🔥 #AJG
A non-inferiority trial comparing 2 days vs. 5 days of terlipressin and ceftriaxone in terms of 5-day rebleeding for patients with acute gastro-esophageal variceal hemorrhage #IDXposts@BradSpellberg#Shorterisbetter?
https://t.co/gJYNcQRZoa
🆕️⚡️ @AJHPOfficial
Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections #IDXposts#PWID
https://t.co/qzvqfCRz7s
🆕️🔥 Systematic Review and Meta-Analysis @OFIDJournal
Investigating Non-Penicillin Therapeutic Strategies in Syphilis Treatment
Penicillin monotherapy did not outperform ceftriaxone, azithromycin, or doxycycline.
#IDXposts https://t.co/kQW4xkdj7d